Based in France, Curlim is an innovative biotech company focused on developing therapeutic solutions for hereditary peripheral neuropathies and rare neurodegenerative diseases. These debilitating conditions, such as Charcot–Marie–Tooth disease (CMT), affect tens of thousands of patients in Europe and the U.S. and currently have no curative treatments. CMT, the most common inherited peripheral neuropathy, affects approximately 1 in 5,000 individuals worldwide representing a major unmet medical need for patients worldwide.

Curlim has developed an innovative encapsulation platform designed to improve the therapeutic efficacy of bioactive molecules for treating hereditary peripheral neuropathies and rare diseases. The benefits are better Solubility, better Stability, better Bioavailability and a significant increase of intra-cellular penetration (Trojan horse) allowing molecules to reach full therapeutic potential.

Curlim obtained unprecedented and spectacular therapeutic effects with significant rescue in the nerve function (demonstrated on 2 CMT1A animal models with no signs of toxicity, even with repeated doses. Some highlights : very significant improvement in Motor Nerve Conduction Velocities (MNCV) in all models and a normalisation of motor skills, with balance time on the bar not statistically different from normal rats.

Moreover, the platform is a flexible solution applicable to multiple drug candidates and therapeutic indications, far beyond neuropathies.

This makes Curlim not just a drug developer, but the owner of a scalable, high-value platform technology with long-term partnering and licensing potential.